perinatologyРоссийский вестник перинатологии и педиатрииRossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)1027-40652500-2228Ltd. “The National Academy of Pediatric Science and Innovation”10.21508/1027-4065-2025-0-5-21-28perinatology-2271Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWSПоражение почек при туберозном склерозеKidney damage in tuberous sclerosishttps://orcid.org/0000-0002-0942-0103МорозовС. Л.MorozovS. L.

Морозов Сергей Леонидович — к.м.н., вед. науч. сотр. отдела наследственных и приобретенных болезней почек им. профессора М.С. Игнатовой НИКИ педиатрии и детской хирургии им. акад. Ю.Е. Вельтищева; доцент кафедры госпитальной педиатрии № 2 института материнства и детства РНИМУ им. Н.И. Пирогова.

125412, Москва; 117513, Москва

125412, Moscow; 117513, Moscow

mser@list.ruhttps://orcid.org/0000-0001-7663-6070ПирузиеваО. Р.PiruzievaO. R.

Пирузиева Оксана Рашидовна — врач-нефролог отделения нефрологии.

125412, Москва, ул. Талдомская, д. 2

125412, Moscow

https://orcid.org/0000-0002-0702-4932ПриходинаЛ. С.PrikhodinaL. S.

Приходина Лариса Серафимовна — д.м.н., зав. отделом наследственных и приобретенных болезней почек имени профессора М.С. Игнатовой НИКИ педиатрии и детской хирургии им. акад. Ю.Е. Вельтищева; проф. кафедры педиатрии имени академика Г.Н. Сперанского дополнительного профессионального образования РМАНПО.

125412, Москва; 125993, Москва

125412, Moscow; 125993, Moscow

ОСП «Научно-исследовательский клинический институт педиатрии и детской хирургии им. акад. Ю.Е. Вельтищева» ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава РФ; ФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И. Пирогова» Минздрава России, 117513, Москва, Российская ФедерацияРоссияVeltischev Research and Clinical Institute for pediatrics and pediatric surgery; Pirogov Russian National Research Medical UniversityRussian FederationОСП «Научно-исследовательский клинический институт педиатрии и детской хирургии им. акад. Ю.Е. Вельтищева» ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава РФРоссияVeltischev Research and Clinical Institute for pediatrics and pediatric surgeryRussian FederationОСП «Научно-исследовательский клинический институт педиатрии и детской хирургии им. акад. Ю.Е. Вельтищева» ФГАОУ ВО РНИМУ им. Н.И. Пирогова Минздрава РФ; ФГОУ ДПО «Российская Медицинская Академия Непрерывного профессионального образования» Минздрава РоссииРоссияVeltischev Research and Clinical Institute for pediatrics and pediatric surgery; Russian Medical Academy of Continuous Professional EducationRussian Federation2025141120257052128Copyright © Ltd. “The National Academy of Pediatric Science and Innovation”, 20252025Ltd. “The National Academy of Pediatric Science and Innovation”Ltd. “The National Academy of Pediatric Science and Innovation”https://www.ped-perinatology.ru/jour/about/submissions#copyrightNoticehttps://www.ped-perinatology.ru/jour/article/view/2271

Туберозный склероз — редкое генетическое заболевание, характеризующееся развитием доброкачественных опухолей в различных органах, включая почки. Поражение почек при туберозном склерозе наиболее часто представлено ангиомиолипомами и кистами, которые могут приводить к различным осложнениям, таким как кровотечения, почечная недостаточность и злокачественная трансформация. В представленной обзорной статье рассматриваются современные представления о патогенезе, клинических проявлениях, диагностике и методах лечения поражения почек при туберозном склерозе, а также перспективы дальнейших исследований в данной области.

Tuberous sclerosis is a rare genetic disease characterized by the development of benign tumors in various organs, including the kidneys. Renal lesions in tuberous sclerosis are most often represented by angiomyolipomas and cysts, which can lead to various complications, such as bleeding, renal failure and malignant transformation. This review article examines current concepts of the pathogenesis, clinical manifestations, diagnostics and treatment methods of renal lesions in tuberous sclerosis, as well as prospects for further research in this area.

детитуберозный склерозкисты почекангиомиолипомыTSC1TSC2сhildrentuberous sclerosisrenal cystsangiomyolipomasTSC1TSC2Работа выполнена в рамках финансирования Госзадания «Клинические и молекулярно-генетические критерии прогнозирования эффективности таргетной терапии поражения почек при туберозном склерозе у детей». № 1024022200001–0–3.2.3;3.2.20 от 1 апреля 2025 г.The work was carried out within the framework of the State Assignment “Clinical and molecular genetic criteria for predicting the effectiveness of targeted therapy for kidney damage in tuberous sclerosis in children”. № 1024022200001–0–3.2.3;3.2.20 dated April 1, 2025.ReferencesBorkowska J., Schwartz R.A., Kotulska K., Jozwiak S. Tuberous sclerosis complex: tumors and tumorigenesis. Int J Dermatol. 2011; 50(1): 13–20. DOI: 10.1111/j.1365-4632.2010.04727.xBorkowska J., Schwartz R.A., Kotulska K., Jozwiak S. Tuberous sclerosis complex: tumors and tumorigenesis. Int J Dermatol. 2011; 50(1): 13–20. DOI: 10.1111/j.1365-4632.2010.04727.xHuang J., Manning B.D. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J. 2008; 412(2): 179–190. DOI: 10.1042/BJ20080281Huang J., Manning B.D. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J. 2008; 412(2): 179–190. DOI: 10.1042/BJ20080281Морозов С.Л, Пирузиева О.Р., Дорофеева М.Ю., Тарасова О.В., Длин В.В. Ангиомиолипомы почек у детей при туберозном склерозе — современное состояние проблемы. Практическая Медицина [Internet]. 2022; 20(2): 45–49 DOI: 10.32000/2072-1757-2022-2-45-49.Morozov S.L., Piruziyeva O.R., Dorofeyeva M.Yu., Tarasova O.V., Dlin V.V. Renal angiomyolipomas in children with tuberous sclerosis — the current state of the problem. Prakticheskaya Meditsina. 2022; 20(2): 45–49. (in Russ) DOI: 10.32000/2072-1757-2022-2-45-49Curatolo P., Bombardieri R., Jozwiak S. Tuberous sclerosis. The Lancet. 2008; 372(9639):657–668. DOI: 10.1016/S0140-6736(08)61279-9Curatolo P., Bombardieri R., Jozwiak S. Tuberous sclerosis. The Lancet. 2008; 372(9639):657–668. DOI: 10.1016/S0140-6736(08)61279-9Northrup H., Krueger D., Northrup H., Krueger D.A., Roberds S., Smith K., et al. Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurology 2013; 49(4): 243–254. DOI: 10.1016/j.pediatrneurol.2013.08.001Northrup H., Krueger D., Northrup H., Krueger D.A., Roberds S., Smith K., et al. Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurology 2013; 49(4): 243–254. DOI: 10.1016/j.pediatrneurol.2013.08.001van Slegtenhorst M., de Hoogt R., Hermans C., Nellist M., Janssen B., Verhoef S., et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997; 277(5327):805–808. DOI: 10.1126/science.277.5327.805van Slegtenhorst M., de Hoogt R., Hermans C., Nellist M., Janssen B., Verhoef S., et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997; 277(5327):805–808. DOI: 10.1126/science.277.5327.805Northrup H., Aronow M.E., Bebin E.M., Bissler J., Darling T.N., de Vries P.J., et al. Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatr Neurol. 2021; 123: 50–66. DOI: 10.1016/j.pediatrneurol.2021.07.011Northrup H., Aronow M.E., Bebin E.M., Bissler J., Darling T.N., de Vries P.J., et al. Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatr Neurol. 2021; 123: 50–66. DOI: 10.1016/j.pediatrneurol.2021.07.011O’Callaghan F.J., Noakes M.J., Martyn C.N., Osborne J.P. An epidemiological study of renal pathology in tuberous sclerosis complex. BJU Int. 2004; 94(6): 853–857. DOI: 10.1111/j.1464-410X.2004.05046.xO’Callaghan F.J., Noakes M.J., Martyn C.N., Osborne J.P. An epidemiological study of renal pathology in tuberous sclerosis complex. BJU Int. 2004; 94(6): 853–857. DOI: 10.1111/j.1464-410X.2004.05046.xMartignoni G., Pea M., Rocca P.C., Bonetti F. Renal pathology in the tuberous sclerosis complex. Pathology. 2003; 35(6): 505–512. DOI: 10.1080/00313020310001619136Martignoni G., Pea M., Rocca P.C., Bonetti F. Renal pathology in the tuberous sclerosis complex. Pathology. 2003; 35(6): 505–512. DOI: 10.1080/00313020310001619136Zöllner J.P., Franz D.N., Hertzberg C., Nabbout R., Rosenow F., Sauter M., et al. A systematic review on the burden of illness in individuals with tuberous sclerosis complex (TSC). Orphanet J Rare dis. 2020; 15(1): 23. DOI: 10.1186/s13023-019-1258-3Zöllner J.P., Franz D.N., Hertzberg C., Nabbout R., Rosenow F., Sauter M., et al. A systematic review on the burden of illness in individuals with tuberous sclerosis complex (TSC). Orphanet J Rare dis. 2020; 15(1): 23. DOI: 10.1186/s13023-019-1258-3Bissler J.J., Kingswood J.C. Optimal treatment of tuberous sclerosis complex associated renal angiomyolipomata: a systematic review. Ther Adv Urol. 2016; 8(4): 279–290. DOI: 10.1177/1756287216641353Bissler J.J., Kingswood J.C. Optimal treatment of tuberous sclerosis complex associated renal angiomyolipomata: a systematic review. Ther Adv Urol. 2016; 8(4): 279–290. DOI: 10.1177/1756287216641353Mekahli D., Müller R-U., Marlais M., Wlodkowski T., Haeberle S., De Argumedo M.L., et al. Clinical practice recommendations for kidney involvement in tuberous sclerosis complex: a consensus statement by the ERKNet Working Group for Autosomal Dominant Structural Kidney Disorders and the ERA Genes & Kidney Working Group. Nat Rev Nephrol. 2024; 20(6): 402–420. DOI: 10.1038/s41581-024-00818-0Mekahli D., Müller R-U., Marlais M., Wlodkowski T., Haeberle S., De Argumedo M.L., et al. Clinical practice recommendations for kidney involvement in tuberous sclerosis complex: a consensus statement by the ERKNet Working Group for Autosomal Dominant Structural Kidney Disorders and the ERA Genes & Kidney Working Group. Nat Rev Nephrol. 2024; 20(6): 402–420. DOI: 10.1038/s41581-024-00818-0Stillwell T.J., Gomez M.R., Kelalis P.P. Renal lesions in tuberous sclerosis. J Urol. 1987; 138(3): 477–481. DOI: 10.1016/s0022-5347(17)43234-4Stillwell T.J., Gomez M.R., Kelalis P.P. Renal lesions in tuberous sclerosis. J Urol. 1987; 138(3): 477–481. DOI: 10.1016/s0022-5347(17)43234-4Подольная М.А., Кобринский Б.А., Белоусова Е.Д., Дорофеева М.Ю., Пивоварова (Горейко) А.М. Регистр больных туберозным склерозом RU 2017620527. 2017Podolnaya M.A., Kobrinsky B.A., Belousova E.D., Dorofeeva M.Yu., Pivovarova (Goreiko) A.M. Tuberous sclerosis patient registry RU 2017620527. 2017 (in Russ)Алтунина Г.Е., Балаян И.Г., Белоусова Е.Д., Березницкая В.В., Божко О.В., Верченко Е.Г., и др. Туберозный склероз. Диагностика и лечение. Адаре. 2017: 288.Altunina G.E., Balayan I.G., Belousova E.D., Bereznitskaya V.V., Bozhko O.V., Verchenko E.G. et al. Tuberous sclerosis. Diagnosis and treatment. Adare. 2017: 288 (in Russ)Морозов С.Л., Пирузиева О.Р., Дорофеева М.Ю., Катышева О.В., Тарасова О.В., Сахарова Е.С. и др. Проблемы поликистоза почек у детей с туберозным склерозом на современном этапе. Медицинский Оппонент. 2022;(3 (19)):45–50.Morozov S.L., Piruziyeva O.R., Dorofeyeva M.YU., Katysheva O.V., Tarasova O.V., Sakharova Y.S., et al. Problems of polycystic kidney disease in children with tuberous sclerosis at the present stage. Meditsinskiy Opponent. 2022;(3 (19)):45–50 (in Russ);Kingswood J.C., d’Augères G.B., Belousova E., Ferreira J.C., Carter T., Castellana R. et al. TuberOus SClerosis registry to increase disease Awareness (TOSCA) — baseline data on 2093 patients. Orphanet J Rare Dis. 2017; 12: 2. DOI: 10.1186/s13023-016-0553-5Kingswood J.C., d’Augères G.B., Belousova E., Ferreira J.C., Carter T., Castellana R. et al. TuberOus SClerosis registry to increase disease Awareness (TOSCA) — baseline data on 2093 patients. Orphanet J Rare Dis. 2017; 12: 2. DOI: 10.1186/s13023-016-0553-5Rouvière O., Nivet H., Grenier N., Zini L., Lechevallier E. Kidney damage due to tuberous sclerosis complex: management recommendations. Diagn Interv Imaging. 2013; 94(3): 225–237. DOI: 10.1016/j.diii.2013.01.003Rouvière O., Nivet H., Grenier N., Zini L., Lechevallier E. Kidney damage due to tuberous sclerosis complex: management recommendations. Diagn Interv Imaging. 2013; 94(3): 225–237. DOI: 10.1016/j.diii.2013.01.003Bains L., Bhatia R., Lal P., Bhagria G. Giant bilateral angiomyolipoma of the kidney. Ann R Coll Surg Engl. 2021. 103(6):e184-e188. DOI: 10.1308/rcsann.2020.7036Bains L., Bhatia R., Lal P., Bhagria G. Giant bilateral angiomyolipoma of the kidney. Ann R Coll Surg Engl. 2021. 103(6):e184-e188. DOI: 10.1308/rcsann.2020.7036Dabora S.L., Jozwiak S., Franz D.N., Roberts P.S., Nieto A., Chung J. et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet. 2001; 68(1): 64–80. DOI: 10.1086/316951Dabora S.L., Jozwiak S., Franz D.N., Roberts P.S., Nieto A., Chung J. et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet. 2001; 68(1): 64–80. DOI: 10.1086/316951Budde K., Gaedeke J. Tuberous Sclerosis Complex–Associated Angiomyolipomas: Focus on mTOR Inhibition. American Journal of Kidney Diseases. 2012; 59(2): 276–283. DOI: 10.1053/j.ajkd.2011.10.013Budde K., Gaedeke J. Tuberous Sclerosis Complex–Associated Angiomyolipomas: Focus on mTOR Inhibition. American Journal of Kidney Diseases. 2012; 59(2): 276–283. DOI: 10.1053/j.ajkd.2011.10.013Kingswood J.C., Belousova E., Benedik M.P., Carter T., Cottin V., Curatolo P. et al. Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease Awareness. Nephrol Dial Transplant. 2019; 34(3): 502–508. DOI: 10.1093/ndt/gfy063Kingswood J.C., Belousova E., Benedik M.P., Carter T., Cottin V., Curatolo P. et al. Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease Awareness. Nephrol Dial Transplant. 2019; 34(3): 502–508. DOI: 10.1093/ndt/gfy063Johnson S.R., Cordier J.F., Lazor R., Cottin V., Costabel U., Harari S. et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J. 2010; 35(1): 14–26. DOI: 10.1183/09031936.00076209Johnson S.R., Cordier J.F., Lazor R., Cottin V., Costabel U., Harari S. et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J. 2010; 35(1): 14–26. DOI: 10.1183/09031936.00076209Muller A., Rouvière O. Renal artery embolization—indications, technical approaches and outcomes. Nat Rev Nephrol. 2015; 11(5): 288–301. DOI: 10.1038/nrneph.2014.231Muller A., Rouvière O. Renal artery embolization—indications, technical approaches and outcomes. Nat Rev Nephrol. 2015; 11(5): 288–301. DOI: 10.1038/nrneph.2014.231Krueger D.A., Northrup H., Northrup H., Krueger D.A., Roberds S., Smith K. et al. Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. PediatricNeurology.2013; 49(4): 255–265Krueger D.A., Northrup H., Northrup H., Krueger D.A., Roberds S., Smith K. et al. Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. PediatricNeurology.2013; 49(4): 255–265Siroky B.J., Czyzyk-Krzeska M.F., Bissler J.J. Renal involvement in tuberous sclerosis complex and von Hippel-Lindau disease: shared disease mechanisms? Nat Clin Pract Nephrol. 2009; 5(3): 143–156. DOI: 10.1038/ncpneph1032Siroky B.J., Czyzyk-Krzeska M.F., Bissler J.J. Renal involvement in tuberous sclerosis complex and von Hippel-Lindau disease: shared disease mechanisms? Nat Clin Pract Nephrol. 2009; 5(3): 143–156. DOI: 10.1038/ncpneph1032Henderson R.J., Germany R., Peavy P.W., Eastham J.A., Venable D.D. Fat density in renal cell carcinoma: demonstration with computerized tomography. J Urol. 1997; 157(4): 1347–1348Henderson R.J., Germany R., Peavy P.W., Eastham J.A., Venable D.D. Fat density in renal cell carcinoma: demonstration with computerized tomography. J Urol. 1997; 157(4): 1347–1348Морозов С.Л., Пирузиева О.Р., Длин В.В. Эффективность таргетной терапии поражения почек при туберозном склерозе у ребенка (клинический случай). Нефрология. 2021; 25(4): 90–94. DOI: 10.36485/1561-6274-2021-25-4-90-94.Morozov S.L., Piruziyeva O.R., Dlin V.V. Efficiency of targeted therapy for kidney damage in tuberous sclerosis in a child (clinical case). Nefrologiya. 2021; 25(4): 90–94. (in Russ). DOI: 10.36485/1561-6274-2021-25-4-90-94Napolioni V., Moavero R., Curatolo P. Recent advances in neurobiology of Tuberous Sclerosis Complex. Brain and Development. 2009; 31(2): 104–113. DOI: 10.1016/j.brain-dev.2008.09.013Napolioni V., Moavero R., Curatolo P. Recent advances in neurobiology of Tuberous Sclerosis Complex. Brain and Development. 2009; 31(2): 104–113. DOI: 10.1016/j.brain-dev.2008.09.013Siroky B.J., Yin H., Bissler J.J. Clinical and Molecular Insights into Tuberous Sclerosis Complex Renal Disease. Pediatr Nephrol. 2011; 26(6): 839–852. DOI: 10.1007/s00467-010-1689-5Siroky B.J., Yin H., Bissler J.J. Clinical and Molecular Insights into Tuberous Sclerosis Complex Renal Disease. Pediatr Nephrol. 2011; 26(6): 839–852. DOI: 10.1007/s00467-010-1689-5Magaki S.D., Vinters H.V. Tuberous Sclerosis Complex. In: Developmental Neuropathology. Editors Adle-Biassette H., Harding B.N., Golden J. Wiley; 2018; 117–131Magaki S.D., Vinters H.V. Tuberous Sclerosis Complex. In: Developmental Neuropathology. Editors Adle-Biassette H., Harding B.N., Golden J. Wiley; 2018; 117–131Игнатова М.С. Кистозы почек у детей с позиций цилиопатий. Педиатрия. Журнал им. Г.Н. Сперанского. 2012; 91(3): 110–116Ignatova M.S. Kidney cysts in children from the standpoint of ciliopathies. Pediatriya. Zhurnal im. G.N. Speranskogo. 2012; 91(3): 110–116 (in Russ)Kleymenova E., Ibraghimov-Beskrovnaya O., Kugoh H., Everitt J., Xu H., Kiguchi K., et al. Tuberin-Dependent Membrane Localization of Polycystin-1. Molecular Cell. 2001; 7(4): 823–832. DOI: 10.1016/S1097-2765(01)00226-XKleymenova E., Ibraghimov-Beskrovnaya O., Kugoh H., Everitt J., Xu H., Kiguchi K., et al. Tuberin-Dependent Membrane Localization of Polycystin-1. Molecular Cell. 2001; 7(4): 823–832. DOI: 10.1016/S1097-2765(01)00226-XKingswood J.C., Belousova E., Benedik M.P., Carter T., Cottin V., Curatolo P. et al. Renal Manifestations of Tuberous Sclerosis Complex: Key Findings From the Final Analysis of the TOSCA Study Focussing Mainly on Renal Angiomyolipomas. Front. Neurol. 2020; 11: 972. DOI: 10.3389/fneur.2020.00972Kingswood J.C., Belousova E., Benedik M.P., Carter T., Cottin V., Curatolo P. et al. Renal Manifestations of Tuberous Sclerosis Complex: Key Findings From the Final Analysis of the TOSCA Study Focussing Mainly on Renal Angiomyolipomas. Front. Neurol. 2020; 11: 972. DOI: 10.3389/fneur.2020.00972Nelson C.P., Sanda M.G. Contemporary diagnosis and management of renal angiomyolipoma. J Urol. 2002; 168(4 Pt 1):1315–1325. DOI: 10.1016/S0022-5347(05)64440-0Nelson C.P., Sanda M.G. Contemporary diagnosis and management of renal angiomyolipoma. J Urol. 2002; 168(4 Pt 1):1315–1325. DOI: 10.1016/S0022-5347(05)64440-0Sooriakumaran P., Gibbs P., Coughlin G., Attard V., Elmslie F., Kingswood C. et al. Angiomyolipomata: challenges, solutions, and future prospects based on over 100 cases treated. BJU Int. 2010; 105(1): 101–106. DOI: 10.1111/j.1464-410X.2009.08649.xSooriakumaran P., Gibbs P., Coughlin G., Attard V., Elmslie F., Kingswood C. et al. Angiomyolipomata: challenges, solutions, and future prospects based on over 100 cases treated. BJU Int. 2010; 105(1): 101–106. DOI: 10.1111/j.1464-410X.2009.08649.xUysal S.P., Şahin M. Tuberous sclerosis: a review of the past, present, and future. Turk J Med Sci. 2020; 50(SI-2):1665–1676. DOI: 10.3906/sag-2002-133Uysal S.P., Şahin M. Tuberous sclerosis: a review of the past, present, and future. Turk J Med Sci. 2020; 50(SI-2):1665–1676. DOI: 10.3906/sag-2002-133Zoncu R., Bar-Peled L., Efeyan A., Wang S., Sancak Y., Sabatini D.M. mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-AT-Pase. Science. 2011; 334(6056):678–683. DOI: 10.1126/science.1207056Zoncu R., Bar-Peled L., Efeyan A., Wang S., Sancak Y., Sabatini D.M. mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-AT-Pase. Science. 2011; 334(6056):678–683. DOI: 10.1126/science.1207056Franz D.N., Belousova E., Sparagana S., Bebin E.M., Frost M., Kuperman R. et al. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Lancet Oncol. 2014; 15(13): 1513–1520. DOI: 10.1016/S1470-2045(14)70489-9Franz D.N., Belousova E., Sparagana S., Bebin E.M., Frost M., Kuperman R. et al. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Lancet Oncol. 2014; 15(13): 1513–1520. DOI: 10.1016/S1470-2045(14)70489-9Bissler J.J., Kingswood J.C., Radzikowska E., Zonnenberg B.A., Frost M., Belousova E. et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013; 381(9869):817–824. DOI: 10.1016/S0140-6736(12)61767-XBissler J.J., Kingswood J.C., Radzikowska E., Zonnenberg B.A., Frost M., Belousova E. et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013; 381(9869):817–824. DOI: 10.1016/S0140-6736(12)61767-XBissler J.J., Budde K., Sauter M., Franz D.N., Zonnenberg B.A., Frost M.D. et al. Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2. Nephrol Dial Transplant. 2019; 34(6): 1000–1008. DOI: 10.1093/ndt/gfy132Bissler J.J., Budde K., Sauter M., Franz D.N., Zonnenberg B.A., Frost M.D. et al. Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2. Nephrol Dial Transplant. 2019; 34(6): 1000–1008. DOI: 10.1093/ndt/gfy132Janssens P., Van Hoeve K., De Waele L., De Rechter S., Claes K.J., Van de Perre E. et al. Renal progression factors in young patients with tuberous sclerosis complex: a retrospective cohort study. Pediatr Nephrol. 2018; 33(11): 2085–2093. DOI: 10.1007/s00467-018-4003-6Janssens P., Van Hoeve K., De Waele L., De Rechter S., Claes K.J., Van de Perre E. et al. Renal progression factors in young patients with tuberous sclerosis complex: a retrospective cohort study. Pediatr Nephrol. 2018; 33(11): 2085–2093. DOI: 10.1007/s00467-018-4003-6Skrzypczyk P., Wabik A.M., Szyszka M., Józwiak S., Bombiński P., Jakimów-Kostrzewa A. et al. Early Vascular Aging in Children With Tuberous Sclerosis Complex. Front Pediatr. 2021; 9: 767394. DOI: 10.3389/fped.2021.767394Skrzypczyk P., Wabik A.M., Szyszka M., Józwiak S., Bombiński P., Jakimów-Kostrzewa A. et al. Early Vascular Aging in Children With Tuberous Sclerosis Complex. Front Pediatr. 2021; 9: 767394. DOI: 10.3389/fped.2021.767394Massella L., Mekahli D., Paripović D., Prikhodina L., Godefroid N., Niemirska A. et al. Prevalence of Hypertension in Children with Early-Stage ADPKD. Clin J Am Soc Nephrol. 2018; 13(6): 874–883. DOI: 10.2215/CJN.11401017Massella L., Mekahli D., Paripović D., Prikhodina L., Godefroid N., Niemirska A. et al. Prevalence of Hypertension in Children with Early-Stage ADPKD. Clin J Am Soc Nephrol. 2018; 13(6): 874–883. DOI: 10.2215/CJN.11401017Sugiura H., Shimada T., Moriya-Ito K., Goto J-I., Fujiwara H., Ishii R. et al. A Farnesyltransferase Inhibitor Restores Cognitive Deficits in Tsc2+/– Mice through Inhibition of Rheb1. J. Neurosci. 2022; 42(12): 2598–2612. DOI: 10.1523/JNEU-ROSCI.0449-21.2022Sugiura H., Shimada T., Moriya-Ito K., Goto J-I., Fujiwara H., Ishii R. et al. A Farnesyltransferase Inhibitor Restores Cognitive Deficits in Tsc2+/– Mice through Inhibition of Rheb1. J. Neurosci. 2022; 42(12): 2598–2612. DOI: 10.1523/JNEU-ROSCI.0449-21.2022Muroga C., Yokoyama H., Kinoshita R., Fujimori D., Yamada Y., Okanishi T. et al. A child with TSC2/PKD1 contiguous gene deletion syndrome successfully treated with tolvaptan for rapidly enlarging renal cysts. CEN Case Rep. 2024; 13(5): 351–355. DOI: 10.1007/s13730-024-00854-6Muroga C., Yokoyama H., Kinoshita R., Fujimori D., Yamada Y., Okanishi T. et al. A child with TSC2/PKD1 contiguous gene deletion syndrome successfully treated with tolvaptan for rapidly enlarging renal cysts. CEN Case Rep. 2024; 13(5): 351–355. DOI: 10.1007/s13730-024-00854-6

The authors declare that there are no conflicts of interest present.